Despite weak Q3 earnings, Bharat Petroleum (BPCL) draws attention from global brokerages. CLSA upgraded BPCL to ‘Hold with a ...

Healthcare stocks see mixed performance as Dr Lal Pathlabs and Aurobindo Pharma rise over 2% after CLSA upgrades their ...

The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

Brokerage firm Nuvama has highlighted concerns about BPCL's weak refining margin environment and LPG under-recoveries, which ...

This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...

CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

The brokerage firm has also added Zomato to its high conviction outperform list, saying the recent correction is a buying ...

India's most valued company, Reliance Industries Ltd (RIL), reported a robust performance in the third quarter of the current ...

CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine months, after missing its third-quarter profit estimates on lower sales and ...

This is the first time Indus Towers has received a ₹575 target, making it the highest among analysts covering the telecom ...